Evotec stock gains 0.35% to EUR 2.90 before Xetra open
Published on 11/05/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Evotec combines molecular patient data, disease models and omics-based research to support drug discovery.
- Just - Evotec Biologics is presented as a growth catalyst, while partnerships can generate milestones, licensing income and revenue shares.
Evotec stock traded at EUR 2.90 on Lang & Schwarz at 07:55 CET on Thursday, November 5, 2026, 0.35 percent above the Xetra close of Wednesday, November 4, at EUR 2.89. Investors can follow the real-time quote of Evotec stock.
Business model remains in focus
Evotec describes its business as drug research and development built on advanced technologies, science and AI-driven innovation. The company combines molecular patient data, patient-based disease models and omics-based drug research to help move medicines from concept toward patients. Its approach is outlined on the Evotec investor relations page.
The stated value chain includes D&PD and Just - Evotec Biologics. Evotec presents the biologics unit as a catalyst for profitable growth through greater use of existing technologies and manufacturing capacity. In partnerships, the company says more complex projects and broader access to proprietary technologies can increase milestone, licensing and commercial-success revenue components.
The broader German equity market remains a relevant backdrop for investors, with the DAX as the main benchmark.
More news and analyses on Evotec stock are available on the company topic page.
